SB-773812
- Generic Name
- SB-773812
- Drug Type
- Small Molecule
- Chemical Formula
- C25H26ClNO4S
- CAS Number
- 630407-66-8
- Unique Ingredient Identifier
- ZNP5SNF9FY
- Background
SB-773812 is under investigation in clinical trial NCT00259870 (SB-773812 Administered in Adults With Schizophrenia).
Effects Of The Drug Ketoconazole On How The Body Handles The Drug SB773812
- First Posted Date
- 2006-12-15
- Last Posted Date
- 2017-08-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 36
- Registration Number
- NCT00411866
- Locations
- 🇬🇧
GSK Investigational Site, Dundee, United Kingdom
SPECT Study With SB-773812 In Schizophrenic Patients
- First Posted Date
- 2005-12-23
- Last Posted Date
- 2017-08-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 95
- Registration Number
- NCT00269035
- Locations
- 🇪🇸
GSK Investigational Site, Vic (Barcelona), Spain
SB-773812 Administered In Adults With Schizophrenia
Phase 2
Completed
- Conditions
- Schizophrenia
- First Posted Date
- 2005-12-01
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 338
- Registration Number
- NCT00259870
- Locations
- 🇷🇺
GSK Investigational Site, St.Petersburg, Russian Federation
In-Patient Study In Schizophrenic Patients
Phase 1
Completed
- Conditions
- Schizophrenia
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2009-05-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 60
- Registration Number
- NCT00197093
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath